grant

UCSD Cancer Center Training Program in Drug Development

Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 1 Jul 2006Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY2025Cancer CenterTraining Programsdrug development
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY/ABSTRACT
This renewal application seeks funding to continue the highly successful Cancer Therapeutics Training (CT2)

Program at the Moores Comprehensive Cancer Center at the University of California, San Diego. About 40% of

Americans will develop cancer in their lifetime. More than 600,000 fall to cancer each year. The mission of the

CT2 program is to train PhD and MD-physician-scientists who will become the next generation of leaders in the

field of cancer drug and therapeutics in each of the major steps required for successful translation of laboratory-

based discoveries into safe and effective therapeutic agents. The CT2 training is designed to position trainees

to play key leadership roles in the field of oncology therapeutics. The 31 faculty of the CT2 Program are all

Members of the Cancer Center and are appointed in 11 departments in the School of Medicine, the Skaggs

School of Pharmacy and Pharmaceutical Sciences or the general campus. Each faculty preceptor is an

accomplished investigator and educator with a history of training superb postdoctoral fellows. Each has

substantial peer-reviewed cancer or cancer-related research funding. All of the participating faculty are

conducting translational research and have been selected because of their interest in new cancer therapeutics.

This program is extensively integrated with other activities of the UC San Diego Moores Cancer Center and the

extensive biotech/pharma industry in San Diego. The goal is to recruit and retain 8 MD and PhD scientists in

this two-year program that will position them for careers in the development of new cancer drugs or the

diagnostics needed to guide the use of these drugs in the era of personalized medicine. The training program

components include: the completion of formal didactic teaching sessions that cover tools essential to the drug

development process; the conduct of one or more steps in therapeutic development research project under the

direction of a faculty preceptor; and required participation in individual development plans, including yearly

attendance at the annual meeting of the American Association for Cancer Research or an equivalent national

meeting. Trainees are also expected to participate in Cancer Center and Departmental seminars, research

rounds, and journal clubs to expand the breadth of their understanding of cancer research and prepare formal

project plans and practice or real grant applications for review by the Executive Committee. Methods are in place

to ensure that all trainees are properly instructed in the principles of responsible conduct of research and

scientific integrity. Trainees are recruited nationwide and special efforts are made recruit and retain exceptional

candidates from groups historically underrepresented in biomedical sciences.

Grant Number: 5T32CA121938-19
NIH Institute/Center: NIH

Principal Investigator: Michael Bouvet

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →